Kirsten Gillibrand and Experts Discuss Pharmaceutical Supply Chain Resilience

Risks of Over-Reliance on Domestic Drug Production

• ⚠️ Relying solely on the United States for drug production carries risks, as demonstrated by recent drug shortages originating within the U.S. due to natural disasters like hurricanes.
• 📌 Geographic concentration of production facilities, even within the U.S., can create vulnerabilities if not properly diversified across different regions (e.g., East Coast vs. West Coast).

Aligning Supply and Demand for Resilience

• 💰 The federal government can promote a resilient supply chain by paying for it, specifically by prioritizing resilience in procurement for vulnerable drugs.
• 🎯 By setting benchmarks for resilience and offering slightly higher prices or longer contracts, the government can incentivize suppliers to meet these standards, making the market more robust.

Diversification and Innovation in Pharmaceutical Supply Chains

• 🌍 Diversifying drug production geographically and across different platforms, including leveraging the innovation of allies, is crucial for resilience.
• 🤝 Companies can achieve cost reductions and resilience by diversifying suppliers for raw materials and precursors, potentially sharing savings to ensure ethical quality standards.

Federal Government's Role in Supply Chain Stress Testing

• 🔬 The federal government, in collaboration with agencies like DLA and FDA, is mapping critical medicines to understand the consequences of disruptions.
• 📈 Regular stress tests simulating worst-case scenarios (e.g., natural disasters, geopolitical conflicts, material shortages) are recommended to identify and address weak points.
• ⚠️ A complete view of the supply chain, extending beyond direct suppliers to all tiers, is necessary to prevent issues like the ventilator solenoid valve shortage during the COVID-19 pandemic.